These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

471 related articles for article (PubMed ID: 25483653)

  • 21. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First results on the DCVax phase III trial: raising more questions than providing answers.
    Wick W; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1283-1284. PubMed ID: 30137551
    [No Abstract]   [Full Text] [Related]  

  • 23. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma.
    Rudnick JD; Sarmiento JM; Uy B; Nuno M; Wheeler CJ; Mazer MJ; Wang H; Hu JL; Chu RM; Phuphanich S; Black KL; Yu JS
    J Clin Neurosci; 2020 Apr; 74():187-193. PubMed ID: 32169363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.
    Ardon H; Van Gool S; Lopes IS; Maes W; Sciot R; Wilms G; Demaerel P; Bijttebier P; Claes L; Goffin J; Van Calenbergh F; De Vleeschouwer S
    J Neurooncol; 2010 Sep; 99(2):261-72. PubMed ID: 20146084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
    Wang X; Zhao HY; Zhang FC; Sun Y; Xiong ZY; Jiang XB
    Cancer Invest; 2014 Nov; 32(9):451-7. PubMed ID: 25259676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide.
    Mitchell DA; Sayour EJ; Reap E; Schmittling R; DeLeon G; Norberg P; Desjardins A; Friedman AH; Friedman HS; Archer G; Sampson JH
    Cancer Immunol Res; 2015 Apr; 3(4):320-5. PubMed ID: 25387895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice.
    Pellegatta S; Poliani PL; Corno D; Grisoli M; Cusimano M; Ubiali F; Baggi F; Bruzzone MG; Finocchiaro G
    Neurol Res; 2006 Jul; 28(5):527-31. PubMed ID: 16808884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.
    Fadul CE; Fisher JL; Hampton TH; Lallana EC; Li Z; Gui J; Szczepiorkowski ZM; Tosteson TD; Rhodes CH; Wishart HA; Lewis LD; Ernstoff MS
    J Immunother; 2011 May; 34(4):382-9. PubMed ID: 21499132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.
    Akiyama Y; Oshita C; Kume A; Iizuka A; Miyata H; Komiyama M; Ashizawa T; Yagoto M; Abe Y; Mitsuya K; Watanabe R; Sugino T; Yamaguchi K; Nakasu Y
    BMC Cancer; 2012 Dec; 12():623. PubMed ID: 23270484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials.
    Lv L; Huang J; Xi H; Zhou X
    Int Immunopharmacol; 2020 Jun; 83():106336. PubMed ID: 32213460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safe and Reproducible Preparation of Functional Dendritic Cells for Immunotherapy in Glioblastoma Patients.
    Nava S; Lisini D; Pogliani S; Dossena M; Bersano A; Pellegatta S; Parati E; Finocchiaro G; Frigerio S
    Stem Cells Transl Med; 2015 Oct; 4(10):1164-72. PubMed ID: 26273063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.